Skip to main content

Table 1 Baseline characteristics of study patients

From: Post-COVID-19 syndrome. SARS-CoV-2 RNA detection in plasma, stool, and urine in patients with persistent symptoms after COVID-19

  N = 29
Median age (IQR)—years 45 (36–56)
Female gender—n (%) 18 (62)
Comorbidities—n (%)  
 Hypertension 1 (3.4%)
 Dyslipidemia 3 (10.3%)
 Obesity 3 (10.3%)
Immunosuppression 2 (6.8%)
Pneumonia COVID-19—n (%) 15 (51.7%)
COVID-19 severity—n (%)  
 Mild 16 (55%)
 Moderate 6 (20%)
 Severe 7 (24%)
Antiviral treatment—n (%) 19 (65%)
COVID-19 severity and having received antiviral treatment—n (%)  
 Mild 6 (37.5%)
 Moderate 6 (100%)
 Severe 7 (100%)
Type antiviral treatment—n (%)  
 lpv/r 15 (78%)
 HCQ 19 (100%)
 Azm 3 (15%)
 lpv/r + HCQ 15 (78%)
 HCQ + Azm 3 (15%)
 Glucocorticoids 2 (10%)
  1. IQR interquartile range, n number, lpv/r  lopinavir/ritonavir, HCQ hydroxychloroquine, Azm Azithromycin